This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Benson Al B III , Venook AP , Cederquist L , Chan E , Chen YJ , Cooper HS , Deming D , Engstrom PF , Enzinger PC , Fichera A , Grem JL , Grothey A , Hochster HS , Hoffe S , Hunt S , Kamel A , Kirilcuk N , Krishnamurthi S , Messersmith WA , Mulcahy MF , Murphy JD , Nurkin S , Saltz L , Sharma S , Shibata D , Skibber JM , Sofocleous CT , Stoffel EM , Stotsky-Himelfarb E , Willett CG , Wu CS , Gregory KM , Freedman-Cass D
Colon cancer, version 1.2017: Clinical practice guidelines in oncology
JNCCN Journal of the National Comprehensive Cancer Network. 2017 Mar;15(3) :370-398
PMID: 28275037 URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85016215716&partnerID=40&md5=459102fde0f31d33e5dd9ca6812a0eae
AbstractThis portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.
NotesExport Date: 1 May 2017